NCT05016947 2026-01-29Venetoclax Plus Inotuzumab for B-ALLDana-Farber Cancer InstitutePhase 1 Active not recruiting23 enrolled
NCT04681105 2026-01-28Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological MalignanciesCity of Hope Medical CenterPhase 1 Completed13 enrolled
NCT03472573 2025-05-15Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaThomas Jefferson UniversityPhase 1 Completed7 enrolled
NCT00866307 2021-04-27Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)Children's Oncology GroupPhase 1 Completed104 enrolled 9 charts
NCT01722305 2019-07-22Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular LymphomaMayo ClinicPhase 1 Completed29 enrolled
NCT01088763 2014-11-05Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaNational Cancer Institute (NCI)Phase 1 Terminated129 enrolled
NCT00003217 2014-07-25Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaChildren's Oncology GroupPhase 1 Completed20 enrolled